Inflammatory breast cancer: what are the treatment options?

Bibliography

• Bell C. A system of operative surgery. Surgery 1814;11:136
   Google Scholar
• Haagensen CD. Diseases of the breast. 2nd edition. Philadelphia: Saunders, 1971;16:829
   Google Scholar
• Greene FL. American Joint Committee on Cancer., and American Cancer Society., AJCC cancer staging manual. 6th edition. New York: Springer-Verlag, 2002;14:421
   Google Scholar
• Kleer CG, van Golen KL, Merajver SD. Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res 2000;2(6):423-9
   PubMedGoogle Scholar
• Chang S, Parker SL, Pham T, Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992. Cancer 1998;82(12):2366-72
   PubMedGoogle Scholar
• Tardivon AA, Viala J, Rudelli AC, Mammographic patterns of inflammatory breast carcinoma: a retrospective study of 92 cases. Eur J Radiol 1997;24(2):124-30
   PubMedGoogle Scholar
• Singletary SE, Cristofanilli M. Defining the clinical diagnosis of inflammatory breast cancer. Semin Oncol 2008;35(1):7-10
   PubMedGoogle Scholar
• Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol 1992;10(6):1014-24
   PubMedGoogle Scholar
• Dershaw DD, Moore MP, Liberman L, Inflammatory breast carcinoma: mammographic findings. Radiology 1994;190(3):831-4
   PubMedGoogle Scholar
• Droulias CA, Sewell CW, McSweeney MB, Inflammatory carcinoma of the breast: a correlation of clinical, radiologic and pathogic findings. Ann Surg 1976;184(2):217-22
   PubMedGoogle Scholar
• Oh JL, Nguyen G, Whitman GJ, Placement of radiopaque clips for tumor localization in patients undergoing neoadjuvant chemotherapy and breast conservation therapy. Cancer 2007;110(11):2420-7
   PubMedGoogle Scholar
• Wingo PA, Jamison PM, Young JL, Population-based statistics for women diagnosed with inflammatory breast cancer (United States). Cancer Causes Control 2004;15(3):321-8
   PubMedGoogle Scholar
• Baslaim MM, Bakheet SM, Bakheet R, 18-Fluorodeoxyglucose-positron emission tomography in inflammatory breast cancer. World J Surg 2003;27(10):1099-104
   PubMedGoogle Scholar
• Beyer T, Townsend DW, Brun T, A combined PET/CT scanner for clinical oncology. J Nucl Med 2000;41(8):1369-79
   PubMedGoogle Scholar
• Dawood S, Broglio K, Gonzalez-Angulo AM, Development of new cancers in patients with DCIS: the M.D. Anderson experience. Ann Surg Oncol 2008;15(1):244-9
   PubMedGoogle Scholar
• McCarthy NJ, Yang X, Linnoila IR, Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. Clin Cancer Res 2002;8(12):3857-62
   PubMedGoogle Scholar
• Parton M, Dowsett M, Ashley S, High incidence of HER-2 positivity in inflammatory breast cancer. Breast 2004;13(2):97-103
   PubMedGoogle Scholar
• Slamon DJ, Godolphin W, Jones LA, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244(4905):707-12
   PubMed Web of Science ®Google Scholar
• Paradiso A, Tommasi S, Brandi M, Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. Cancer 1989;64(9):1922-7
   PubMedGoogle Scholar
• Alpaugh ML, Tomlinson JS, Shao ZM, A novel human xenograft model of inflammatory breast cancer. Cancer Res 1999;59(20):5079-84
   PubMedGoogle Scholar
• van Golen KL, Davies S, Wu ZF, A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 1999;5(9):2511-9
   PubMedGoogle Scholar
• Bertucci F, Finetti P, Rougemont J, Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res 2004;64(23):8558-65
   PubMed Web of Science ®Google Scholar
• Wu M, Wu ZF, Kumar-Sinha C, RhoC induces differential expression of genes involved in invasion and metastasis in MCF10A breast cells. Breast Cancer Res Treat 2004;84(1):3-12
   PubMedGoogle Scholar
• Bertucci F, Finetti P, Rougemont J, Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res 2005;65(6):2170-8
   PubMedGoogle Scholar
• Haagensen CD, Stout AP. Carcinoma of the breast: II. Criteria of pperability. Ann Surg 1943;118(5):859-70
   PubMedGoogle Scholar
• Robbins GF, Shah J, Rosen P, Inflammatory carcinoma of the breast. Surg Clin North Am 1974;54(4):801-10
   PubMedGoogle Scholar
• Gonzalez-Angulo AM, Hennessy BT, Broglio K, Trends for inflammatory breast cancer: is survival improving? Oncologist 2007;12(8):904-12
   PubMedGoogle Scholar
• Merajver SD, Weber BL, Cody R, Breast conservation and prolonged chemotherapy for locally advanced breast cancer: the University of Michigan experience. J Clin Oncol 1997;15(8):2873-81
   PubMedGoogle Scholar
• Anderson JM. Inflammatory carcinomas of the breast. Ann Royal Coll Surg Engl 1980;62(3):195
   PubMedGoogle Scholar
• Jessup JM, Blumenschein GR, Montague ED, Management of inflammatory carcinoma of the breast. A combined modality approach. Am J Clin Oncol 1985;8(2):134
   PubMedGoogle Scholar
• Bonadonna G, Valagussa P, Viganotti G, Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol 1978;1(1):53
   PubMedGoogle Scholar
• May-Levin F, Papacharalambous A, Spielmann M, Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy. J Clin Oncol 1986;4(12):1765
   PubMedGoogle Scholar
• Casper ES, Guidera CA, Bosl GJ, Combined modality treatment of locally advanced breast cancer: adjuvant combination chemotherapy with and without doxorubicin. Breast Cancer Res Treat 1987;9(1):39
   PubMedGoogle Scholar
• Lippman ME, Steinberg SM, Wesley MN, Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res 1987;47(14):3889
   PubMedGoogle Scholar
• Terasawa T, Koyama H, Nishizawa Y, Management of inflammatory carcinoma of the breast with combined modality therapy including intraarterial infusion chemotherapy as an induction therapy. Long-term follow-up results of 28 patients. Cancer 1988;61(8):1483
   PubMedGoogle Scholar
• Jung G, Haennel P, Jaeck D, Results of initial doxorubicin, 5-fluorouracil, and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast. Cancer 1990;65(4):851
   PubMedGoogle Scholar
• Theriault RL, Hug V, Fraschini G, Inflammatory carcinoma of the breast: results of a combined-modality approach–M.D. Anderson Cancer Center experience. Cancer Chemother Pharmacol 1990;27(2):94
   PubMedGoogle Scholar
• Schwartz GF, Birchansky CA, Komarnicky LT, Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 1994;73(2):362-9
   PubMedGoogle Scholar
• Solin L, Glick J, Fox K, Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys 2003;55(5):1200
   PubMedGoogle Scholar
• Hurteloup P, Chollet P, Olivier JP, Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993. 16(3):223
   PubMedGoogle Scholar
• Limentani SA, Brufsky AM, Erban JK, Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. J Clin Oncol 2007;25(10):1232-8
   PubMedGoogle Scholar
• Cristofanilli M, Buzdar AU, Sneige N, Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer 2001;92(7):1775
   PubMedGoogle Scholar
• Cristofanilli M, Gonzalez-Angulo A, Buzdar A, Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. Clini Breast Cancer 2004;4(6):415
   PubMedGoogle Scholar
• Untch M, Mbus V, Kuhn W, Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol 2009;27(18):2938
   PubMedGoogle Scholar
• Hurley J, Doliny P, Reis I, Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 2006;24(12):1831-8
   PubMedGoogle Scholar
• Fields KK, Elfenbein GJ, Perkins JB, Defining the role of novel high-dose chemotherapy regimens for the treatment of high-risk breast cancer. Semin Oncol 1998;25(2 Suppl 4):1
   PubMedGoogle Scholar
• Schwartzberg L, Weaver C, Lewkow L, High-dose chemotherapy with peripheral blood stem cell support for stage IIIB inflammatory carcinoma of the breast. Bone Marrow Transplant 1999;24(9):981
   PubMedGoogle Scholar
• Dazzi C, Cariello A, Rosti G, Neoadjuvant high dose chemotherapy plus peripheral blood progenitor cells in inflammatory breast cancer: a multicenter phase II pilot study. Haematologica 2001;86(5):523
   PubMedGoogle Scholar
• Sports C, Steinberg S, Liewehr D, Strategies to improve long-term outcome in stage IIIB inflammatory breast cancer: multimodality treatment including dose-intensive induction and high-dose chemotherapy. Biol Blood Marrow transplant 2009;15(8):963
   PubMedGoogle Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Harris LN, Gelman R, Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003;21(1):46-53
   PubMedGoogle Scholar
• Dawood S, Gonzalez-Angulo AM, Peintinger F, Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience. Cancer 2007;110(6):1195-200
   PubMedGoogle Scholar
• Van Pelt AE, Mohsin S, Elledge RM, Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer 2003;4(5):348-53
   PubMedGoogle Scholar
• Rusnak DW, Affleck K, Cockerill SG, The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res 2001;61(19):7196-203
   PubMedGoogle Scholar
• Kaufman B, Trudeau M, Awada A, Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol 2009;10(6):581-8
   PubMed Web of Science ®Google Scholar
• Borgstrom P, Gold DP, Hillan KJ, Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 1999;19(5B):4203-14
   PubMedGoogle Scholar
• Wedam SB, Low JA, Yang SX, Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006;24(5):769-77
   PubMedGoogle Scholar
• Giordano SH, Hortobagyi GN. Inflammatory breast cancer: clinical progress and the main problems that must be addressed. Breast Cancer Res 2003;5(6):284-8
   PubMedGoogle Scholar
• Barker JL, Montague ED, Peters LJ. Clinical experience with irradiation of inflammatory carcinoma of the breast with and without elective chemotherapy. Cancer 1980;45(4):625-9
   PubMedGoogle Scholar
• Schafer P, Alberto P, Forni M, Surgery as part of a combined modality approach for inflammatory breast carcinoma. Cancer 1987;59(6):1063-7
   PubMedGoogle Scholar
• Liao Z, Strom EA, Buzdar AU, Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence. Int J Radiat Oncol Biol Phys 2000;47(5):1191-200
   PubMedGoogle Scholar
• Bristol IJ, Woodward WA, Strom EA, Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. Int J Radiat Oncol Biol Phys 2008;72(2):474-84
   PubMedGoogle Scholar
• Bozzetti F, Saccozzi R, De Lena M, Inflammatory cancer of the breast: analysis of 114 cases. J Surg Oncol 1981;18(4):355-61
   PubMedGoogle Scholar
• Treves N. The inoperability of inflammatory carcinoma of the breast. Surg Gynecol Obstet 1959;109(2):240-2
   PubMedGoogle Scholar
• Perez CA, Graham ML, Taylor ME, Management of locally advanced carcinoma of the breast. I. Noninflammatory. Cancer 1994;74(1 Suppl):453-65
   PubMedGoogle Scholar
• Panades M, Olivotto IA, Speers CH, Evolving treatment strategies for inflammatory breast cancer: a population-based survival analysis. J Clin Oncol 2005;23(9):1941-50
   PubMedGoogle Scholar
• Calais G, Berger C, Descamps P, Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm. Cancer 1994;74(4):1283-8
   PubMedGoogle Scholar
• Stearns V, Ewing CA, Slack R, Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol 2002;9(3):235-42
   PubMedGoogle Scholar
• Perloff M, Lesnick GJ, Korzun A, Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: a Cancer and Leukemia Group B study. J Clin Oncol 1988;6(2):261-9
   PubMedGoogle Scholar
• Palangie T, Mosseri V, Mihura J, Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer 1994;30A(7):921-7
   PubMedGoogle Scholar
• Veyret C, Levy C, Chollet P, Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial. Cancer 2006;107(11):2535-44
   PubMedGoogle Scholar